One-Week Versus Two-Week Furazolidone-Based Quadruple Therapy As the First-Line Treatment for Helicobacter Pylori Infection in Iran Publisher



Daghaghzadeh H² ; Emami MH^{2, 3} ; Karimi S¹ ; Raeisi M²
Source: Journal of Gastroenterology and Hepatology (Australia) Published:2007

Abstract

Background and Aim: Furazolidone-based regimens for the eradication of Helicobacter pylori are low cost and effective although less tolerable. Our aim was to compare the efficacy and compliance of 1-week furazolidone-based quadruple therapy (furazolidone, amoxicillin, bismuth subcitrate, omeprazole; FABO) with 2-week quadruple therapy using the same drugs. Methods: One hundred and fifty-six consecutive patients with H. pylori related diseases were enrolled in our study. The patients were randomized into two groups of FABO1 and FABO2 groups receiving, 1 or 2 weeks' quadruple H. pylori eradication therapies, respectively, as follows: furazolidone (200 mg twice daily), amoxicillin (1 g twice daily), bismuth (240 mg twice daily) and omeprazole (20 mg twice daily). The χ2 test was used to compare the efficacy of the therapies. Results: The per-protocol eradication rate in FABO1 and FABO2 groups were 56/66 (84.8%) and 57/69 (82.6%), respectively. The intention-to-treat eradication rate was 56/78 (71.8%) in FABO1 group and 57/78 (73.1%) in FABO2 group. There was not any significant statistical difference between two groups. A significant decrease in compliance in FABO2 group was seen. Conclusion: This is an encouraging report showing a therapy with possible success in decreasing the duration of H. pylori infection as well as reaching the eradication rate of 80%. © 2007 The Authors.